Saturday, January 28, 2017 6:03:40 PM
Granted there still aren't a "lot" of shares outstanding ,so the stock can still move but ... if they hadn't done the R/SPLIT and issued the shares they did the share count would have risen to 60-80 million depending on who is doing the counting.
That's a lot of dilution in such a short period of time
Question is ... does the market see that because shares are still under 10 million .... I mean they say when a R/split is done nothing "theoretically" changes ... well it does when you sell that many shares in such a short period of time After the R/split
I guess IDXG was thinking along these lines ... "Well we can do a R/split and then dump a lot of shares and no one will be the wiser ... the market has short term memory after a period of time they'll start buying it up again"
Revenues might be what people want to see now before they give it a higher price tag because of their uncontrolled Capital raises
We'll see ...
That's a lot of dilution in such a short period of time
Question is ... does the market see that because shares are still under 10 million .... I mean they say when a R/split is done nothing "theoretically" changes ... well it does when you sell that many shares in such a short period of time After the R/split
I guess IDXG was thinking along these lines ... "Well we can do a R/split and then dump a lot of shares and no one will be the wiser ... the market has short term memory after a period of time they'll start buying it up again"
Revenues might be what people want to see now before they give it a higher price tag because of their uncontrolled Capital raises
We'll see ...
"Diversification is a protection against ignorance. It makes very little sense for those who know what they're doing."
Recent IDXG News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2026 08:15:35 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 09:38:48 PM
- Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results • GlobeNewswire Inc. • 03/30/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 09:05:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 11:46:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/20/2026 02:05:32 PM
- Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Revenue Guidance and Simplification of Capital Structure • GlobeNewswire Inc. • 01/20/2026 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/03/2025 09:05:28 PM
- Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners • GlobeNewswire Inc. • 12/03/2025 05:12:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 09:45:44 PM
- Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results • GlobeNewswire Inc. • 11/12/2025 09:01:00 PM
- Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting • GlobeNewswire Inc. • 09/15/2025 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:28:44 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2025 08:30:40 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2025 08:28:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2025 08:25:28 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/28/2025 08:27:54 PM
